{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T19:01:00.419747+00:00","company":{"ticker":"AIDX","cik":1139685,"company_name":"20/20 Biolabs, Inc."},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"governance_change","fact_key":"595e42d86a8af6bf27cba8755d5f21bc9a844b25","cik":1139685,"ticker":"AIDX","company_name":"20/20 Biolabs, Inc.","filed_at":"2026-05-26T20:28:45+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2026-05-19","item_codes_triggered":["5.03"],"summary_text":"Reduced the quorum required for a meeting of stockholders from a majority of the shares outstanding to one-third of the shares outstanding."},"claim":"20/20 Biolabs, Inc.: Reduced the quorum required for a meeting of stockholders from a majority of the shares outstanding to one-third of the shares outstanding (effective 2026-05-19).","evidence_excerpt":"On May 19, 2026, the Board of Directors of 20/20 Biolabs, Inc. (the “ Company ”) adopted Amendment No. 1 to the Company’s Amended and Restated Bylaws (the “ Amendment ”), pursuant to which Section 2.5 of the Company’s Amended and Restated Bylaws was amended to reduce the quorum required for a meeting of stockholders from a majority of the shares outstanding to one-third of the shares outstanding.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-061039","anchor_url":"https://secwatch.observer/filing/0001213900-26-061039#claim-595e42d86a8af6bf27cba8755d5f21bc9a844b25","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026061039/0001213900-26-061039-index.htm"},{"fact_type":"earnings_release","fact_key":"b3c1a9949e2c559ae2767680333f15a26167408c","cik":1139685,"ticker":"AIDX","company_name":"20/20 Biolabs, Inc.","filed_at":"2026-04-01T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"($3.7) million","period_text":"the full year ended December 31, 2025","report_date":"2026-03-31","result_type":"reported_results","revenue_text":"$2.0 million"},"claim":"20/20 Biolabs, Inc. reported the full year ended December 31, 2025 results: revenue $2.0 million, net income ($3.7) million.","evidence_excerpt":"Revenue of $2.0 million for FY 2025, representing an increase of 17% over FY 2024. ● Deferred revenue totaled approximately $0.4 million as of December 31, 2025. ● Gross profit of $0.6 million for FY 2025, representing an increase of 68% over FY 2024. Gross margin was 29.6% in FY 2025, compared to 20.6% in FY 2024. ● Total operating expenses decreased 35% to $3.9 million in FY 2025 compared to $6.0 million in FY 2024. ● FY 2025 net loss improved 33% to ($3.7) million, compared to ($5.6) million in FY 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-037770","anchor_url":"https://secwatch.observer/filing/0001213900-26-037770#claim-b3c1a9949e2c559ae2767680333f15a26167408c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026037770/0001213900-26-037770-index.htm"}]}